Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Frequency of actionable cancer predisposing germline mutations in patients with lung cancers
    Meeting Abstract

    Mukherjee, S.; Zauderer, M. G.; Ravichandran, V.; Kemel, Y.; Mandelker, D.; Pradhan, N.; Zehir, A.; Lipkin, S. M.; Srinivasan, P.; Bandlamudi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Phase I study of intermittent high-dose lapatinib alternating with capecitabine for HER2-positive breast cancer with central nervous system metastases
    Meeting Abstract

    Morikawa, A.; Pentsova, E.; Kemeny, M.; Patil, S.; Li, B. T.; Tang, K.; Fleisher, M.; Van Poznak, C. H.; Norton, L.; Seidman, A. D.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes of EGFR-mutant lung adenocarcinomas (AC) that transform to small cell lung cancer (SCLC)
    Meeting Abstract

    Marcoux, N.; Gettinger, S. N.; O'Kane, G. M.; Arbour, K. C.; Neal, J. W.; Husain, H.; Evans, T. L.; Brahmer, J. R.; Muzikansky, A.; Bonomi, P.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • In vitro functional analysis of HER2 variants in lung cancers to evaluate their oncogenic activity and predict response to HER2-targeted therapy
    Meeting Abstract

    Liu, D.; Offin, M. D.; Olah, Z. T.; Tarcic, G.; Zelichov, O.; Vidne, M.; Drilon, A. E.; Arcila, M. E.; Li, B. T.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Real-world data (RWD) on tumor response (rwTR) in advanced non-small cell lung cancer (aNSCLC) patients receiving cancer immunotherapy and targeted therapies
    Meeting Abstract

    Lu, M.; Sadetsky, N.; Lambert, P.; Whipple, S.; Taylor, M. D.; Riehl, T.; Riely, G. J.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Li, B. T.; Makker, V.; Buonocore, D. J.; Offin, M. D.; Olah, Z. T.; Panora, E.; Shen, R.; Ho, A. L.; Yaeger, R.; Iyer, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Frequency of brain metastases and outcomes in patients with HER2-, KRAS-, and EGFR-mutant lung cancers
    Meeting Abstract

    Kris, M. G.; Offin, M. D.; Feldman, D. L.; Ni, A.; Lai, W. C. V.; Arbour, K. C.; Daras, M.; Pentsova, E.; DeAngelis, L. M.; Beal, K.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutation burden and response to immune checkpoint blockade in patients with HER2-mutant lung cancers
    Meeting Abstract

    Lai, W. C. V.; Feldman, D. L.; Buonocore, D. J.; Brzostowski, E. B.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Sabari, J. K.; Offin, M. D.; Kris, M. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC)
    Meeting Abstract

    Kim, D. W.; Gadgeel, S. M.; Gettinger, S. N.; Riely, G. J.; Oxnard, G. R.; Mekhail, T.; Schmid, P.; Dowlati, A.; Heist, R. S.; Wozniak, A. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Safety and activity of durvalumab + tremelimumab in immunotherapy (IMT)-retreated advanced NSCLC patients
    Meeting Abstract

    Garon, E. B.; Spira, A. I.; Goldberg, S. B.; Chaft, J. E.; Papadimitrakopoulou, V.; Antonia, S. J.; Brahmer, J. R.; Camidge, D. R.; Powderly, J. D.; Wozniak, A. J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save